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It is generally assumed that the inbred mouse strains BALB/c (H-2d) and C57BL/6 (H-2b) respond to
mycobacterial infection with distinct polarisation of T helper responses, with C57BL/6 predisposed to Th1
and BALB/c to Th2. We investigated this in a BCG-immunisation, Mycobacterium bovis challenge model.
Following immunisation, lung and spleen cell cytokine responses to in vitro re-stimulation with a cocktail
of seven secreted, immunogenic, recombinant mycobacterial proteins were determined. In both lung and
spleen, BALB/c cells produced at least 2-fold more IFN-g, and up to 7-fold more IL-2 and IL-17 than
C57BL/6 cells, whereas IL-10 production was reciprocally increased in C57BL/6 mice. These data suggest
that, contrary to reports in the literature, speciﬁc mycobacterial antigens are able to induce strong Th1
and Th17 responses in BALB/c mice following BCG vaccination, whilst in C57BL/6 mice, the Th1 response
is partly counterbalanced by IL-10. After subsequentM. bovis low dose challenge, protection, as measured
in the lungs and dissemination to the spleen, was equivalent in BALB/c and C57BL/6 mice, indicating that
BCG-induced immunity was equivalent in both strains. Thus, the differential immune responses do not
appear to have a role in protection, but further, as yet unidentiﬁed, speciﬁc immune responses play a
signiﬁcant role.
Crown Copyright © 2014 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
In inbred mouse strains, defense against intracellular pathogens
such as mycobacteria, salmonella and leishmania involves an early
innate immune response and a late adaptive cell-mediated im-
munity with T lymphocytes being the main effector cells. The
innate response is mainly controlled by the expression of the single
dominant gene Bcg/Ity/Lsh which affects the ability of the murine
host to restrict proliferation of these pathogens within macro-
phages [1,2]. The strains BALB/c (H-2d) and C57BL/6 (H-2b) bear the
same susceptible allele of the Bcg/Ity/Lsh gene (2), but have shown
contrasting susceptibilities to certain intracellular pathogens. Thus,
BALB/c mice are susceptible to Leishmania major, Yersinia enter-
ocolitica and Chlamydia trachomatis infection, whereas C57BL/6
mice are resistant [3e6]. Such dichotomy was linked to the balance
between T helper cell populations; leishmania infection triggers a
strong Th2 response in susceptible BALB/c mice, characterized by
increased production of IL-4 and IL-10, whereas resistant C57BL/6J. Hogarth).
vier Ltd. This is an open access artimice preferentially activate Th1 cells producing IFN-g and IL-12
[3,4]. A similar shift towards Th1 responses in C57BL/6 and Th2 in
BALB/c was also reported in response to mycobacterial vaccination;
C57BL/6 mice exhibiting an enhanced protective immunity to
intravenous re-challenge with Mycobacterium bovis BCG (BCG)
when compared to BALB/c [7]. The lack of a strong protective
response in BALB/c has been associated with a reduced ability to
express the Th1 cytokine IL-12, and subsequent lower levels of IFN-
g [8]. Furthermore, treatment of BALB/c mice with recombinant IL-
12 enhanced host defense against intravenous Mycobacterium
tuberculosis infection [9]. Another study suggested that the sup-
pressed Th1 response to mycobacterial infection in BALB/c mice
was not a result of an enhanced Th2 response; BALB/c mice
developed a greater early innate response, but failed to develop a
strong Th1 response compared to C57BL/6 mice [10].
Experimental studies have therefore shown divergent results on
the immune proﬁle and the nature of responses to mycobacterial
infections inmice of different genetic backgrounds. In this studywe
analysed the cytokine secretion proﬁle of lymphocytes derived
from BCG immunised C57BL/6 and BALB/c mice and compared
protective immunity after intranasal challenge with virulent
M. bovis. Contrary to previous studies, we found that BCGcle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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with increased levels of IFN-g, IL-2 and IL-17, whereas C57BL/6mice
producedmore IL-10, characteristic of a Th2 response. Interestingly,
BCG vaccination generated comparable protective immunity in
both strains, indicating that the differential immune responses
observed do not have a critical role in protection against primary
infection with M. bovis.
2. Materials & methods
2.1. Ethics statement
All animal work was carried out in accordance with the UK
Animal (Scientiﬁc Procedures) Act 1986; under appropriate per-
sonal and project licences. The study protocol was approved by the
APHA Animal Use Ethics Committee (UK Home Ofﬁce PCD number
70/6905).
2.2. Animals
Female BALB/c and C57BL/6 mice were obtained from SPF fa-
cilities at Charles River UK Ltd and used at 8 weeks of age. All an-
imals were housed in appropriate containment facilities at APHA.
2.3. Mycobacteria
The vaccination strain used was the human vaccineM. bovis BCG
Danish 1331, prepared as per manufacturer's instructions (SSI,
Denmark).
M. bovis isolate AF2122/97 was grown to mid-log phase in
Middlebrook 7H9 broth (Gibco, UK) supplemented with 4.16 g/L
pyruvic acid, 10% v/v OADC and 0.05% v/v Tween 80 (all Sigma, UK),
subsequently frozen at 80 C, and used for all virulent challenges.
2.4. Mycobacterial antigens
A cocktail of 7 secreted, immunogenic recombinant mycobac-
terial proteins (Rv1886c, Rv0251, Rv0287, Rv0288, Rv3019c,
Rv3763, and Rv3804c) was used for antigen-speciﬁc stimulation.
Rv1886, Rv3019c, Rv3804c and Rv3763 were purchased from
Lionex GmbH, Germany. Rv0251, Rv0287 and Rv0288 were pur-
chased from Proteix s.r.o., Czech Republic.
2.5. Immunisation and mycobacterial challenge
Mice were immunized with a single intradermal (i.d.) injection
of 2  105 CFU of BCG. Placebo control mice were immunized with
PBS. Six weeks following immunisation, mice were either chal-
lenged intranasally (i.n.) with approx. 400 CFU of virulent M. bovis,
as previously described [11], or euthanised and the lungs and
spleens removed for cell isolation prior to immunological assays.
Intranasal challenge in our laboratory results in retention of 75% of
the administered dose to the lungs [11]. Four weeks after challenge,
the mice were euthanized and the lungs and spleens removed and
homogenised. These homogenates were serially diluted and plated
out on modiﬁed Middlebrook 7H11 agar media [12]. Bacterial col-
onies were enumerated four weeks later following incubation at
37 C.
2.6. Cell isolations and stimulations
Spleen, and interstitial lung lymphocytes were prepared as
previously described [13]. Cells were cultured with a pool of 7 re-
combinant antigens as described, each antigen at a ﬁnal concen-
tration of 2 mg/ml for all assays.2.7. IFN-g ELISPOT
5  105 cells were incubated in duplicate in 96 well ﬁlter plates
(MSIPS4510Millipore, Ireland) with or without antigen for 16 h and
the frequency of IFN-g secretors detected by ELISPOT (Mabtech,
Sweden), as per manufacturer's instructions.2.8. Cytokine production
Spleen and lung interstitial lymphocytes (5  106/ml) were
cultured in the presence of antigen cocktail for 72 h (37 C/5% CO2)
prior to harvest of supernatant. Production of IFN-g, TNF-a, IL-2, IL-
4, IL-6, IL-10, IL-12, IL-17 and IL-22 was measured by a capture
ELISA using the Mesoscale Discovery (MSD®, Mesoscale, USA)
platform according to manufacturer's instructions.2.9. Statistical analyses
All data were analysed by 1-way ANOVA with Tukey's post test,
using GraphPad Instat 3 statistical package (GraphPad, USA).
Mycobacterial counts were previously log10 transformed and ELISA/
ELISPOT data were corrected by subtracting the unstimulated from
the antigen-stimulated culture values prior to analysis.3. Results
3.1. Frequency of IFN-g producing cells after BCG vaccination
Given the importance of IFN-g responses in protection against
tuberculosis, we evaluated the frequency of antigen-speciﬁc IFN-g
producing cells by ELISPOT six weeks after BCG immunisation, by
in vitro re-stimulation with a cocktail of mycobacterial antigens. In
the spleen (Figure 1A), vaccination induced a signiﬁcantly greater
frequency of IFN-g secretors compared to the placebo controls in
both BALB/c and C57BL/6 strains, indicating functional Th1 cells.
The frequency of secretors was similar between both strains with a
mean value of 613 SFU/million cells in BALB/c and 619 SFU/million
cells in C57BL/6. In the lungs, however (Figure 1B), whilst vacci-
nation induced a signiﬁcant increase in IFN-g secreting cells in both
strains; the frequency was signiﬁcantly higher in BALB/c (924 vs.
578 SFU/million cells) indicating a stronger mucosal antigen-
speciﬁc immune response.
In order to compare these data to previously published studies,
we evaluated the frequency of IFN-g producing cells using PPD-B to
stimulate responses. PPD was a less potent inducer of IFN-g pro-
ducing cells (Figure 2A), even used at 5 times normal concentration
at 50 mg/ml. In vaccinated mice, PPD stimulated a maximum of 186
SFU/million cells in BALB/c and 102 SFU/million cells in C57BL/6
strains, more than threefold lower than the M7 cocktail responses
described in Figure 1, and not signiﬁcantly higher than naïve con-
trols. Despite this poor performance, the frequency of Th1 re-
sponders induced by BCG vaccination was greater (N.S.) in BALB/c
than C57BL/6 mice when stimulated by PPD.
Although deﬁned, M7 still represents a mixture of antigens.
To investigate strain differences & potential MHC restriction in
antigen recognition following vaccination, spleen cells from
BALB/c and C57BL/6 were subjected to IFN-g ELISPOT six weeks
after BCG immunisation and re-stimulated in vitro with the in-
dividual antigens of the M7 cocktail (Figure 2B). BALB/c mice
responded exclusively to Rv0288 and C57BL/6 to Rv0287, whilst
both strains responded to Rv3019c & Rv3763 & M7, indicating
that the M7 cocktail induces a balanced response in both
strains.
Figure 2. Frequency of IFN-g secreting cells in spleen from BALB/c/or B6 mice
immunised i.d. with 2  105 CFU of BCG six weeks earlier. Following a 16 h re-
stimulation in vitro with 10 or 50 mg PPD-B (A), or the individual components of M7
cocktail (B), cells were enumerated for IFN-g production by ELISPOT. Results are shown
as means ± SEM for groups of 6 mice; ***p < 0.001, BALB/c M7 vs C57BL/6.
Figure 1. Frequency of IFN-g secreting cells in spleen (A) and lung (B) from BALB/c or
C57BL/6 mice immunised i.d. with 2  105 CFU of BCG six weeks earlier. Following a
16 h re-stimulation in vitro with a cocktail of 7 mycobacterial recombinant proteins,
cells were enumerated for IFN-g production by ELISPOT. Bars represent means ± SEM
(n ¼ 6); **p < 0.01, ***p < 0.001, versus naive controls; *p < 0.05, BCG BALB/c versus
BCG C57BL/6. Data representative of 2 independent studies.
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To further characterize the antigen-speciﬁc immune response
induced by BCG, we assessed the magnitude of the mucosal and
systemic cytokine responses six weeks after vaccination. After
in vitro re-stimulation of lung and spleen cell cultures with a
cocktail of mycobacterial antigens, cytokine production was
measured by ELISA. BCG vaccinated BALB/c splenocytes produced
signiﬁcantly higher levels of both the type 1 cytokines IFN-g and IL-
2; and the type 17 cytokines IL-17 and IL-22 than C57BL/6 vacci-
nates (Figure 3). In contrast, BCG vaccination of C57BL/6, induced
signiﬁcantly higher levels of the immunosuppressive cytokine IL-
10, compared to BALB/c. In lung lymphocyte cultures (Figure 4),
the pattern of responses was broadly similar, with signiﬁcant in-
creases in the production of IFN-g, IL-4, IL-6, TNF-a, IL-2, IL-17 and
IL-22 in BALB/c and signiﬁcantly higher levels of IL-10 in C57BL/6.
Interestingly, as with the IFN-g ELISPOT, antigen-speciﬁc responses
from C57BL/6 lung derived lymphocytes are signiﬁcantly lower, in
magnitude as well as frequency.3.3. Protective efﬁcacy of BCG against M. bovis infection
We next compared the vaccine induced protection between
BALB/c and C57BL/6mice after low dose i.n. challengewithM. bovis.
Mice were challenged six weeks after vaccination, and bacterialload (CFU) assessed in lungs and spleen four weeks after challenge.
As shown in Figure 5, both in spleen (A) and lungs (B) BALB/c and
C57BL/6 mice showed a signiﬁcant reduction in the bacterial
burden when compared to the placebo controls, thus indicating
that BCG vaccination induces protection in both strains. Further-
more, BCG induced protection was similar in both strains with a
bacterial reduction in the spleen of approximately 1.4 Log10 CFU in
BALB/c and 1.3 Log10 CFU in C57BL/6. Similar results were found in
the lungs with a reduction of 1.3 Log10 CFU and 1.2 Log10 CFU in
BALB/c and C57BL/6, respectively.4. Discussion
The aim of this study was to assess the nature of the immune
responses and subsequent protection against M. bovis challenge
elicited by BCG vaccination in two murine hosts with different
genetic backgrounds; BALB/c (H-2d) and C57BL/6 (H-2b). We report
that, despite displaying equivalent levels of protection, there are
distinct differences in the immune response to vaccination, some of
which challenge the commonly accepted dogma regarding these
two commonly utilized strains.
BALB/c mice are capable of developing a fully functional adap-
tive Th1 immune response after a single BCG immunisation, as
indicated by the induction of a signiﬁcant frequency of both sys-
temic and mucosal IFN-g secreting cells coupled to the signiﬁcant
production of other Th1 cytokines. Overall this Th1 response was
Figure 3. Cytokine production in spleen cell cultures from BALB/c or C57BL/6 mice immunised i.d. with 2  105 CFU of BCG six weeks earlier. The cells were stimulated in vitro for
72 h with a cocktail of 7 mycobacterial recombinant proteins. Bars represent means ± SEM (n ¼ 6); *p < 0.05, **p < 0.01, BCG BALB/c versus BCG C57BL/6. Data representative of 2
independent studies.
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alent in C57BL/6 derived cells. Previous studies, however, have re-
ported a signiﬁcantly lower Th1 response in BALB/c after systemic
or pulmonary BCG infection when compared to C57BL/6 mice
[7,9,10]. This discrepancy with our studies may be due to several
reasons:
i) The difference in the recall antigens used for in vitro re-
stimulation: PPD vs. a cocktail of mycobacterial proteins in our
experiments. In support of this hypothesis, we found Th1 re-
sponses to be threefold lower, and not signiﬁcantly above con-
trols in when PPD-B was used for re-stimulation either at 10 or
50 mg/ml (Figure 2A). Despite this poor response to PPD, the
trend toward a higher response observed in BALB/c further
support our observations. These low PPD-speciﬁc responses are
a consistent feature in our model and have been repeated in
BALB/c mice a number of times.
ii) Previous studies utilised different strains of BCG and different
immunisation routes. Our experiments used a human vaccine
preparation (BCG Danish 1331) without in vitro growth and
employed the intradermal immunisation route to closely match
human vaccination protocols. In contrast, for example, Huygen
et al. [7], used intravenous administration of pellicle grown BCG
Pasteur GL2; whilst Wakeham et al. [10], used intra-tracheal
admin of broth grown BCG Connaught.With such variation between experimental conditions, it is
therefore perhaps not so surprising that discrepancies in reported
results occur.
Assessing the magnitude and frequency of key cytokines, such
as IFN-g has remained the standard measurement of vaccine
induced immune responses for many years. It has become clear
recently, however, that these relatively simple in vitro assays cannot
entirely describe the complexity of the immune responses to
vaccination [14]. These assays must therefore be interpreted with
care as it is well documented that ESAT-6 and PPD stimulated IFN-g
correlates with bacterial load [15e17] whilst TB10.3 (Rv3019c) and
TB10.4 (Rv0288) induced responses strongly correlate with pro-
tection [18,19]. Thus, in the current study we have used a deﬁned
cocktail of secreted, strongly antigenic proteins to circumvent this
bias towards a single antigen or ill deﬁned crude preparation
potentially skewing the results.
We found that, following BCG vaccination, the frequency and
magnitude of IFN-g secretion are positively correlated in the
mucosal response, but not at the systemic level; the frequency of
secretors in the spleen is equal in both strains, but the total levels of
IFN-g are higher in BALB/c, suggesting a lower production of IFN-g
on a per cell basis in C57BL/6.
Another important observation of this study was that BALB/c
mice exhibited a stronger Th17 response after BCG vaccination, as
measured by IL-17 and IL-22. Increasing evidence suggests the
Figure 4. Cytokine production in lung cell cultures from BALB/c or C57BL/6 mice immunised i.d. with 2  105 CFU of BCG six weeks earlier. The cells were stimulated in vitro for 72 h
with a cocktail of 7 mycobacterial recombinant proteins. Bars represent means ± SEM (n ¼ 6); *p < 0.05, **p < 0.01, ***p < 0.001, BCG BALB/c versus BCG C57BL/6. Data representative
of 2 independent studies.
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pathogens in murine models (reviewed in [20]) and cattle [21,22].
IL-17 induces direct bacterial killing by macrophages [23,24], and
DC derived IL-12 to differentiate Th1 cells [23]. Recent data suggest
IL-17 drives BCG-speciﬁc Th1 cells responses by overcoming IL-10
inhibition [25]. Consistent with these ﬁndings, our results
showed that BALB/cmice secreted a higher amount of IL-17 coupledFigure 5. Protective efﬁcacy in the BCG vaccinated and M. bovis challenged BALB/c or C57B
400 CFU ofM. bovis. Four weeks postechallenge the mice were euthanised and the bacterial b
(n ¼ 8); ***p < 0.001 versus naïve controls.with a high secretion of IFN-g and a decreased level of IL-10, both at
the systemic and the lungmucosal level. Reciprocally, C57BL/6mice
displayed lower IL-17 and IFN-g and increased IL-10.
Genetic differences between the two strains could account for
this higher level of adaptive Th17 responses observed in BALB/c
mice, although mechanisms remain to be understood at this point.
Earlier studies have demonstrated genes within the MHC inﬂuenceL/6 mice. Six weeks after BCG vaccination, animals were intranasally challenged with
urden (CFU) was measured in the spleens (A) or lungs (B). Bars represent means ± SEM
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triggering signiﬁcant differences in the production of IFN-g after
stimulation with mycobacterial antigens [29].
An effective Th1 immune response is essential for vaccine-
induced protection against infection with virulent mycobacteria
[32]. Therefore, we tested whether reduced BCG-induced Th17 and
Th1 responses affected protection in the M. bovisechallenged
C57BL/6 mice, but found that both mouse strains displayed similar
levels of protection. Thus, it is clear that measurement of more IFN-
g production does not necessarily correlate with better protection
against M. bovis infection. These ﬁndings are in agreement with
previous studies showing that the ability to generate a large
number of Th1 cells does not determine the ability to resist
M. tuberculosis infection in BALB/c and C57BL/6 mice [33]. This has
clear implications for vaccine development since it is generally
assumed that vaccines able to stimulate the production of a larger
number of Th1 cells would be more protective. If the resistance to
M. bovis is not solely based in the Th1 cell component of immunity,
as we understand it at present, then providing a host with the
ability to generate more Th1 cells may have little or no advanta-
geous consequences.
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